Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (17792)	3/24/1998 10:45:00 AM
From: Flagrante Delictu	Read Replies (3) \| Respond to of 32384

Henry, H & Q has just produced a statistical summary of the stocks they follow. For LGND, they show a book value of 49 cents per share, 39.3 million shares outstanding, $635 million in market value at a stock price of $16 on 3/18/98, latest 12 month revenue of $9 million, and a rating of "buy". Their highest rating would be "strong buy". They define "strong buy" as " outperform the S & P 500 index over a three-month period", while "buy" is defined as "outperform the S & P 500 index over a six-month period". The analyst following the company is Richard van den Broeck, whose '98 earnings estimate is [ 0.51] . There is nothing else of consequence listed on LGND in the report. Bernie An interesting question for R. v. d. Broeck would be, " What made [him] change from listing LGND as his favorite bio pick at the end of the '97 H & Q bio conference to a mere "buy" this year. If anyone can easily access him, the answer would be appreciated.